Precigen (Precigen) Change In Working Capital : $17.07 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Precigen Change In Working Capital?

Precigen's change in working capital for the quarter that ended in Dec. 2023 was $16.45 Mil.

Precigen's change in working capital for the fiscal year that ended in Dec. 2023 was $17.07 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Precigen Change In Working Capital Historical Data

The historical data trend for Precigen's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Change In Working Capital Chart

Precigen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-20.65

-0.80

-35.70

17.07

Precigen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-10.76	-0.71	1.21	0.12	16.45

Precigen Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.07 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Precigen Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Precigen's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen (Precigen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

I5X:Germany I5X:Germany

Address

20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website

http://www.precigen.com

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Executives

Jeffrey B Kindler	director	35 E. 62ND ST, NEW YORK NY 10065
Randal J Kirk	director, 10 percent owner, officer: Chief Executive Officer	1881 GROVE AVENUE, RADFORD VA 24141
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari	director, officer: President and CEO	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah	officer: Chief Operating Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian	officer: Chief Financial Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Jeffrey Thomas Perez	officer: SVP, IP Affairs	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Donald P. Lehr	officer: Chief Legal Officer	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro	director	155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez	director	C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley	director	9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a.	10 percent owner	ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170